^
    Back
    Association details:
    Biomarker:PPP2R2B underexpression
    Cancer:HER2 Positive Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Nature
    Title:

    EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy

    Published date:
    11/18/2020
    Excerpt:
    PPP2R2B expression showed marked downregulation in the relapsed metastatic tumors compared to the primary tumors (P = 0.0035...), suggesting a correlation between PPP2R2B downregulation and trastuzumab resistance.
    DOI:
    10.1038/s41467-020-19704-x